| Name | Title | Contact Details |
|---|
NantHealth is a transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system. NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions. NantHealth is a subsidiary of NantWorks a company founded and led by Dr. Patrick Soon-Shiong. NantWorks is a convergence of next generation machine vision, object and voice recognition technologies, ultra-low power semiconductors, supercomputing, and advanced networks for the purpose of bringing the digital revolution to healthcare, commerce, and digital entertainment to an entirely new level. NantHealth envisions a world in which cutting-edge developments in science, technology, infrastructure and human ingenuity converge to advance one extraordinary mission: transforming healthcare for the benefit of every patient. We merge innovation with infrastructure; empowering more efficient and effective clinical decisions through advanced and actionable health information. By improving the accuracy and timeliness of data, we can deliver targeted healthcare intelligence for evolutionary personalized care. Our ultimate mission is to empower progress through uniquely informed decisions; to bring the impossible to life by harnessing the power of convergence for the well-being of humanity.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
GCG Healthcare Group is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BHcare is a state-licensed, non-profit behavioral health care provider serving the Lower Naugatuck Valley, Greater New Haven, and Shoreline communities. For more than 30 years, BHcare – through its founding organizations, Birmingham Group Health Services and Harbor Health Services – has been providing hope and help for individuals, families and children affected by mental illness, domestic violence and substance abuse.
Powerful Ingredients for Real Results